Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Using Incentives to Improve Parolee Participation and Attendance in Community Treatment (PIP)

9. května 2017 aktualizováno: Michael Prendergast, University of California, Los Angeles

Using Incentives to Improve Parolee Participation and Attendance in Community Tx

Under funding from the National Institute on Drug Abuse, the UCLA Integrated Substance Abuse Programs (ISAP), in collaboration with Walden House and the California Department of Corrections and Rehabilitation, is conducting a five-year study that will involve a randomized test of the use of incentives with parolees in a community-based residential substance abuse treatment program to increase treatment admission and treatment retention, and thereby increase the likelihood of improved outcomes. Study participants will be recruited from clients in a prison-based treatment program who have a referral to the Walden House community program. The Admission Phase of the study assesses the effect of an incentive (voucher) on enrolling in the Walden House program. The Attendance Phase assesses the effect of incentives on treatment attendance and on post-treatment drug use, crime, and psychosocial behaviors, including HIV risk behaviors. In addition, an incentive protocol will test whether an incentive will encourage participation in HIV testing and counseling. The intervention will last for six months.

Hypothesis 1. The use of incentives will significantly increase subject enrollment in community treatment.

Hypothesis 2. The use of incentives will significantly increase subject retention in community treatment.

Huypothesis 3. The use of incentives will significantly increase subject participation in HIV testing and counseling.

Study participants will be interviewed at baseline and at 12 months following the intervention. Treatment and criminal justice data will be obtained. Data on acceptability, satisfaction, and sustainability will be collected from focus groups with staff and clients.

Přehled studie

Detailní popis

A considerable body of research indicates that prison-based treatment followed by continuing treatment in the community is effective in reducing drug abuse and crime among drug-abusing offenders. However, the impact of providing treatment is less than optimal because offenders often fail to follow through on treatment referrals, leave treatment early, or have poor engagement in treatment activities. In particular, participation in prison-based treatment alone is seldom effective in reducing drug use or recidivism unless it is followed by participation in community treatment. For correctional systems that provide a continuum of care model from prison to community, low rates of admission and retention result in poor outcomes and poor resource utilization. One way to address this problem is to provide incentives to parolees for community treatment participation. Although research supports the effectiveness of behavioral reinforcement, mainly in the form of contingency management (CM), for general substance abuse populations, CM has not yet been tested or adapted for use in community-based programs for offender populations, particularly to encourage treatment attendance.

In addition, recent research has documented elevated rates of HIV infection among incarcerated populations compared to the general population, with prevalence of HIV among inmates in US prisons being estimated to be 6 to 10 times higher than in the general population. Upon release from prison, parolees often immediately resume high-risk behaviors that they engaged in prior to incarceration. Because of the high level of exposure to HIV infection that accompanies drug use, particularly by injection, drug treatment programs for high-risk offenders can serve as a valuable setting for preventing the spread of HIV, both through HIV prevention/education activities and through access to HIV testing and counseling.

Under funding from the National Institute on Drug Abuse, the UCLA Integrated Substance Abuse Programs (ISAP), in collaboration with Walden House and the California Department of Corrections and Rehabilitation, is conducting a five-year study that will involve a randomized test of the use of incentives with parolees in a community-based residential substance abuse treatment to increase treatment admission and treatment retention, and thereby increase the likelihood of improved outcomes. Study participants will be recruited from clients in a prison-based treatment program who have a referral to the Walden House community program. The Admission Phase of the study assesses the effect of an incentive (voucher) on enrolling in the Walden House program. The Attendance Phase assesses the effect of incentives on treatment attendance and on post-treatment drug use, crime, and psychosocial behaviors, including HIV risk behaviors. In addition, an incentive protocol will test whether an incentive will encourage participation in HIV testing and counseling. The intervention will last for six months.

Hypothesis 1. The use of incentives will significantly increase subject enrollment in community treatment.

Hypothesis 2. The use of incentives will significantly increase subject retention in community treatment.

Huypothesis 3. The use of incentives will significantly increase subject participation in HIV testing and counseling.

Study participants will be interviewed at baseline and at 12 months following the intervention. Treatment and criminal justice data will be obtained. Data on acceptability, satisfaction, and sustainability will be collected from focus groups with staff and clients.

Typ studie

Intervenční

Zápis (Aktuální)

202

Fáze

  • Nelze použít

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

18 let a starší (Dospělý, Starší dospělý)

Přijímá zdravé dobrovolníky

Ne

Pohlaví způsobilá ke studiu

Mužský

Popis

Inclusion Criteria:

  • At least 18 years of age
  • English speaking
  • Within one month of parole
  • Able to provide informed consent to participate in the study
  • Received a referral to the Walden House Los Angeles Transitional Treatment Center

Exclusion Criteria:

  • Potential subjects will be excluded from participating if they have serious cognitive problems that preclude their ability to provide informed consent or understanding of the questionnaire items, if they are a sexually violent predator or a child molester or if they have severe mental health problems.

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Léčba
  • Přidělení: Randomizované
  • Intervenční model: Paralelní přiřazení
  • Maskování: Žádné (otevřený štítek)

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Aktivní komparátor: Attendance Information Group
Participants in the Attendance Information Group will receive an individual information session along with a pamphlet describing the benefits of remaining in treatment after release from prison and on the benefits of HIV prevention and testing. In addition, they will receive the standard treatment offered by the Walden House Los Angeles program.
Attendance Information Group will receive an individual information session along with a pamphlet describing the benefits of remaining in treatment after release from prison and on the benefits of HIV prevention and testing.
Experimentální: Attendance Incentive Group
Participants in the Attendance Incentive Group could receive up to $841.50 in incentives for their treatment attendance and the standard treatment offered by the Walden House Los Angeles program.
Contingency management: Escalation with reset for non-attendance. Daily. Up to $841.50 in incentives for treatment attendance.

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Časové okno
Community treatment admission
Časové okno: Within 7 days of release to parole
Within 7 days of release to parole
Community treatment retention
Časové okno: 6 months
6 months
Participation in HIV testing and counseling
Časové okno: 2 months
2 months

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Substance abuse
Časové okno: 18 months after release from prison
18 months after release from prison
Arrest and reincarceration
Časové okno: 18 months after release from prison
18 months after release from prison
psychosocial: employment, education, family relationships, psychological functioning, and HIV risk
Časové okno: 18 months after release from prison
employment, education, family relationships, psychological functioning, and HIV risk
18 months after release from prison

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Vyšetřovatelé

  • Vrchní vyšetřovatel: Michael L Prendergast, Ph.D., University of California, Los Angeles
  • Ředitel studie: Elizabeth A Hall, Ph.D., University of California, Los Angeles

Publikace a užitečné odkazy

Osoba odpovědná za zadávání informací o studiu tyto publikace poskytuje dobrovolně. Mohou se týkat čehokoli, co souvisí se studiem.

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia

1. dubna 2010

Primární dokončení (Aktuální)

1. ledna 2014

Dokončení studie (Aktuální)

1. srpna 2014

Termíny zápisu do studia

První předloženo

16. března 2010

První předloženo, které splnilo kritéria kontroly kvality

18. března 2010

První zveřejněno (Odhad)

19. března 2010

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

10. května 2017

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

9. května 2017

Naposledy ověřeno

1. května 2017

Více informací

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

Klinické studie na HIV infekce

Klinické studie na Information

Předplatit